Barosense bags $27M for obesity treatment
Barosense, maker of a device to treat obesity without invasive surgery, has brought in $27 million of a targeted $30 million fourth round of funding that it plans to use to commercialize its product, reports PE Hub. It kicked off the round in March, and said it had commitments from its existing investors.
This turned out to be true, with the Redwood City, Calif. company tapping previous backers Delphi Ventures, Frazier Healthcare Ventures, Invesco Private Capital,… Continue Reading
Cardiac monitor maker iRhythm looks to insiders for $6.5M
iRhythm Technologies, maker of a recently-launched cardiac monitoring device, has raised an additional $6.5 million in a first round of funding from existing investors, bringing the two-year-old round’s total to $19 million. Based in San Francisco, the company will use the money to more widely market its product after getting the Food and Drug Administration’s stamp of approval earlier this year.
It should be enough to push iRhythm to break even, the company says. All of… Continue Reading
Barosense looks to raise $30M to market obesity device
Barosense, creator of a minimally-invasive device that can treat obesity, has announced its intent to raise $30 million in a fourth round of funding to commercialize its product. Already many of its existing investors have pledged to provide half that amount, including Delphi Ventures, Frazier Healthcare Ventures, Invesco Private Capital, RWI Ventures, Synergy Life Science Partners and Wharton Ventures.
Based in Menlo Park, Calif., Barosense says it expects to close this round by the end of… Continue Reading
Life sciences briefing: Thursday, Jan. 17, 2007
TODAY’S HEADLINES:
TransEnterix gets $21M for minimally invasive GI surgery (release)
Stem-cell developer Bioheart’s IPO postponed (Forbes.com)
Medical-practice software provider AdvancedMD acquired by Francisco Partners (release)
Peptimmune draws $8.2M for MS drug trials (release)
Drug-delivery co. Talima Thera names Martin Babler CEO (release)
Alimera Sciences aims for autumn IPO to fund diabetic eye-disease drug (VentureWire, sub req’d)
TransEnterix gets $21M for minimally invasive GI surgery — TransEnterix (no Web site), a Research Triangle Park, N.C., device maker developing tools for “natural orifice”… Continue Reading
Secretive Oraya raises more funds for eye devices
Oraya, a secretive Menlo Park, Calif., medical-device startup, has struck again. The company raised $18 million in what is presumably a second funding round, VentureWire reports (subscription required). Investors included Synergy Life Science Partners (see yesterday’s coverage of this newish VC firm here) and Essex Woodlands Health Ventures. We covered Oraya’s first round of funding last June.
VentureWire says the company is working on some sort of unspecified ophthalmology device, which is certainly more than we… Continue Reading
IRhythm, cardiac monitoring device co., raises $12.5M
IRhythm Technologies, a secretive San Francisco start-up (no Web site) developing a cardiac-rhythm monitoring device, has raised $12.5 million in a first round of venture capital, according to PEHub.
Investos are Mohr Davidow Ventures and Synergy Life Science Partners. Company management includes Stanford fellow Uday Kumar and former CardioNet executive William Willis.
InnerPulse, abnormal heart rhythms treatment co., raises $50M
InnerPulse, a North Carolina company developing treatments for abnormal heart rhythms, said it has raised $50 million in new equity financing.
The syndicate of investors included Johnson & Johnson Development Corporation, Medtronic, Inc., Synergy Life Science Partners, Ascent Biomedical Ventures, Delphi Ventures and Frazier Heathcare Ventures. Additonally, Boston Scientific and Greatbatch, Inc. remain significant stockholders of InnerPulse, the company said.
From the statement:
The Company’s products employ an innovative technology to simplify the implant utilizing a minimally… Continue Reading
Delphi and Frazier to sell stake in life-sciences incubator, Synecor
Delphi Ventures and Frazier Healthcare Ventures are selling the minority stake they own in medical-device incubator company Synecor LLC to venture capital firms Ascent Biomedical Ventures and Synergy Life Science Partners, according to VentrueWire (sub required). The transaction has not been finalized yet.
Delphi and Frazier have invested several million dollars in Synecor, based in Portola Valley, Calif. In 2000, they led a $14 million Series A round, which also included General Electric Medical Systems, Guidant… Continue Reading